Cardiologist Weighs In on Negative Vytorin Study This week, the makers of the drug Vytorin released a long-awaited study that raises questions about whether the drug has an impact in reducing the incidence of heart attacks and strokes. Dr. Stuart Seides has prescribed the drug to his patients selectively and says he will continue to do so, despite the study.
NPR logo

Cardiologist Weighs In on Negative Vytorin Study

  • Download
  • <iframe src="https://www.npr.org/player/embed/18121641/18121627" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
Cardiologist Weighs In on Negative Vytorin Study

Cardiologist Weighs In on Negative Vytorin Study

Cardiologist Weighs In on Negative Vytorin Study

  • Download
  • <iframe src="https://www.npr.org/player/embed/18121641/18121627" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

This week, the makers of the drug Vytorin released a long-awaited study that raises questions about whether the drug has an impact in reducing the incidence of heart attacks and strokes.

Dr. Stuart Seides, associate director of cardiology at the Washington Hospital Center, has prescribed the drug to his patients selectively and says he will continue to do so despite the study.

Seides talks with Melissa Block.